Emphysema News and Research RSS Feed - Emphysema News and Research

Emphysema is a debilitating disease that afflicts more than three million Americans. The disease is caused primarily by smoking and leads to a progressive, irreversible breakdown of lung tissue. This breakdown reduces the amount of lung tissue available for gas exchange and also impairs the lung's ability to inflate and deflate normally. As the disease advances, the most damaged areas of the lung over inflate within the chest cavity, trapping air and preventing the healthier lung areas from functioning normally. Eventually breathing becomes more difficult, leaving patients constantly feeling out-of-breath.
Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. [More]
Study demonstrates longer-term benefits of Lung Flute for COPD patients

Study demonstrates longer-term benefits of Lung Flute for COPD patients

Patients with chronic obstructive pulmonary disease (COPD) report improved symptoms and health status when they use a hand-held respiratory device called the Lung Flute-, according to a new study by the University at Buffalo. Usually caused by smoking, COPD, which includes chronic bronchitis and emphysema, is the third leading cause of death in the U.S. [More]
Distinct features of COPD–asthma overlap syndrome identified

Distinct features of COPD–asthma overlap syndrome identified

US researchers have shown that patients with both chronic obstructive pulmonary disease and asthma have more exacerbations, less emphysema and more airway disease than patients with COPD alone. [More]
Biochemists discover proteins that could lead to better treatments for life-threatening infections

Biochemists discover proteins that could lead to better treatments for life-threatening infections

Two Kansas State University biochemists have discovered a family of proteins that could lead to better treatments for Staphylococcus aureus, a pathogenic bacterium that can cause more than 60,000 potentially life-threatening infections each year. [More]
Greater Toronto Area continues to violate Canada-wide standards for ozone air pollution

Greater Toronto Area continues to violate Canada-wide standards for ozone air pollution

A new study shows that while the Greater Toronto Area has significantly reduced some of the toxins that contribute to smog, the city continues to violate the Canada-wide standards for ozone air pollution. [More]
Study finds link between common respiratory diseases and increased risk of lung cancer

Study finds link between common respiratory diseases and increased risk of lung cancer

Links between a number of common respiratory diseases and an increased risk of developing lung cancer have been found in a large pooled analysis of seven studies involving more than 25,000 individuals. [More]
Chronic obstructive pulmonary disease flare-ups: an interview with Dr. MeiLan Han, University of Michigan and Scott Cerreta, Director of Education, COPD Foundation

Chronic obstructive pulmonary disease flare-ups: an interview with Dr. MeiLan Han, University of Michigan and Scott Cerreta, Director of Education, COPD Foundation

During a flare-up, symptoms of a patient’s COPD worsen significantly, and breathing becomes more difficult. A persistent increase in shortness of breath, cough and sputum production are typical symptoms. [More]
Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Xenex Disinfection Services, the world leader in UV room disinfection systems, testified yesterday before the U.S. House of Representatives Committee on Science, Space, and Technology; Subcommittee on Research and Technology; and Subcommittee on Oversight. [More]
Exchange plans attract sicker consumers

Exchange plans attract sicker consumers

An analysis of early medical claims shows that Americans enrolled in the health law's exchange plans have higher rates of serious health problems, according to The Wall Street Journal. Meanwhile, The Washington Post reports that some small employers buying coverage for their workers are struggling with costs and logistics. [More]
First Edition: June 25, 2014

First Edition: June 25, 2014

Today's headlines include a report about a recent analysis that finds new health plan enrollees are showing high rates of serious health conditions. [More]
National, state air pollution controls decrease death rates in North Carolina

National, state air pollution controls decrease death rates in North Carolina

National and state air pollution controls that went into effect in the early 1990s coincide with decreasing death rates from emphysema, asthma and pneumonia among people in North Carolina, according to a study led by Duke University researchers. [More]
Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Patients with combined pulmonary fibrosis and emphysema who are undergoing treatment for advanced lung cancer do not have a significantly worse prognosis than their counterparts with isolated idiopathic interstitial pneumonias, report Japanese researchers. [More]
Researchers identify tremendous genetic diversity

Researchers identify tremendous genetic diversity

In the most comprehensive genetic study of the Mexican population to date, researchers from UC San Francisco and Stanford University, along with Mexico's National Institute of Genomic Medicine (INMEGEN), have identified tremendous genetic diversity, reflecting thousands of years of separation among local populations and shedding light on a range of confounding aspects of Latino health. [More]
New imaging software measures growth of nodules in patients at risk of lung cancer

New imaging software measures growth of nodules in patients at risk of lung cancer

Medical-imaging software under development at Rochester Institute of Technology could someday give radiologists a tool for measuring the growth of nodules in patients at risk of lung cancer, the leading cause of cancer deaths in the United States, according to the Center for Disease Control and Prevention. [More]
X-ray dark-field radiography creates higher resolution images of lung disease

X-ray dark-field radiography creates higher resolution images of lung disease

Scientists at the Helmholtz Zentrum München (HMGU) working in cooperation with the Ludwig-Maximilians-Universität Hospital (KUM) and the Technischen Universität München (TUM) tested for the first time X-ray dark-field radiography on a living organism for the diagnosis of lung disease. [More]
Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD). [More]
Healthy diet provides lots of health benefits for patients with COPD

Healthy diet provides lots of health benefits for patients with COPD

Sure, everyone knows a healthy diet provides lots of health benefits for patients with respiratory diseases, but now a new study has shown a direct link between eating fish, fruit and dairy products and improved lung function among patients with chronic obstructive pulmonary disease (COPD). [More]
GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GlaxoSmithKline plc today presented data at the American Thoracic Society (ATS) from a late-stage clinical study. [More]
Study shows commonly used statin drug does not reduce acute COPD exacerbations

Study shows commonly used statin drug does not reduce acute COPD exacerbations

A statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD), according to the results of a large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA. [More]
Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of the Company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema). [More]